ANT Neuro is pleased to announce a strategic collaboration with Neuronetics, Inc., maker of the NeuroStar® Advanced Therapy System, to make ANT Neuro’s visor2™ neuronavigation system available to NeuroStar TMS providers in the United States.
Through this partnership, Neuronetics will offer visor2 alongside NeuroStar TMS, giving providers access to intuitive neuronavigation workflows that unlock the full potential of personalized TMS treatment planning and delivery. Designed for everyday clinical use, visor2 helps practices visualize stimulation targets, guide coil positioning, and document navigated TMS sessions with confidence.
With precise optical tracking and flexible workflows, visor2 supports clinicians in delivering personalized TMS procedures while fitting into existing clinical routines. With or without MRI images, visor2 adapts to a wide range of TMS practices, from scalp-based navigation to individualized fMRI-guided targeting.
" We are pleased to partner with Neuronetics to bring advanced neuronavigation technology to the leading TMS platform in the market. Together, we aim to provide clinicians with tools that support visualization, consistency, and confidence throughout the treatment process."
" We are excited about the opportunity this collaboration creates for new and existing NeuroStar providers. By combining NeuroStar’s established TMS platform with ANT Neuro’s neuronavigation technology, we are continuing to invest in innovations aligned with the evolving needs of TMS providers. "
About visor2™
visor2 is ANT Neuro’s FDA 510(k)-cleared TMS neuronavigation system for clinical applications in the U.S. market.
The system combines patient-specific 3D visualization with advanced optical tracking to ensure consistent coil positioning throughout the treatment protocol. Designed to improve the precision and accuracy of TMS delivery, visor2 helps clinicians plan and navigate TMS procedures with or without MRI images. The system can be integrated into everyday clinical workflows while also supporting advanced targeting approaches, including individualized fMRI-guided targeting.
Designed with clinical practicality in mind, visor2 features a compact and ergonomic footprint that fits easily into most treatment rooms without interfering with existing equipment or workflows. Its modular design allows practices to configure the system according to their needs, with options including single- or dual-screen setups and integrated EMG capabilities.
In addition to its availability for NeuroStar providers through this partnership, visor2 continues to support broad TMS stimulator compatibility and is compatible with a broad range of FDA-cleared TMS stimulators and coils, enabling practices using a variety of TMS systems to benefit from advanced neuronavigation.
The strategic collaboration with Neuronetics, Inc. was recently showcased at leading U.S. industry meetings, including the American Psychiatric Association Annual Meeting and the Clinical TMS Society Annual Meeting, with a broader rollout planned for the second half of 2026.